NCT06038461: An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 40 planned
- Started
- 15 Sep 2023
- Primary completion
- 15 Sep 2027
- Arms
- Surufatinib Combined With Temozolomide and S-1
- Results
- None posted
- 14 Sep 2023: Trial registered
- 15 Sep 2023: Trial started